CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
Abstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of carbohydrate antigen 125 (CA125) and transvaginal ultrasound (TVU), despite low sensitivity and specificity. We evaluated the association between CA125 levels, BRCA1/2 mutation status and menopausal stat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11116-6 |
| _version_ | 1797789729419165696 |
|---|---|
| author | P Gebhart CF Singer D Gschwantler-Kaulich |
| author_facet | P Gebhart CF Singer D Gschwantler-Kaulich |
| author_sort | P Gebhart |
| collection | DOAJ |
| description | Abstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of carbohydrate antigen 125 (CA125) and transvaginal ultrasound (TVU), despite low sensitivity and specificity. We evaluated the association between CA125 levels, BRCA1/2 mutation status and menopausal status to provide more information on clinical conditions that may influence CA125 levels. Methods We retrospectively analyzed repeated measurements of CA125 levels and clinical data of 466 women at high risk for ovarian cancer. CA125 levels were compared between women with and without deleterious mutations in BRCA1/2. Pearson's correlation was used to determine the association between age and CA125 serum level. Differences in CA125 levels were assessed with the Mann–Whitney U test. The effect of BRCA1/2 mutation status and menopausal status on the change in CA125 levels was determined by Two-factor analysis of variance (ANOVA). Results The CA125 serum levels of premenopausal women (median, 13.8 kU/mL; range, 9.4 – 19.5 kU/mL) were significantly higher than in postmenopausal women (median, 10.4 kU/mL; range, 7.7 – 14.0 kU/mL; p < .001). There was no significant difference in the CA125 levels of BRCA mutation carriers and non-mutation carriers across all age groups (p = .612). When investigating the combined effect of BRCA1/2 mutation and menopausal status, variance analysis revealed a significant interaction between BRCA1/2 mutation status and menopausal status on CA125 levels (p < .001). There was a significant difference between the CA125 levels of premenopausal and postmenopausal women, with a large effect in BRCA mutation carriers (p < .001, d = 1.05), whereas in non-mutation carriers there was only a small effect (p < .001, d = 0.32). Conclusion Our findings suggest that hereditary mutations in BRCA1/2 affect the decline of CA125 levels with increasing age. To prove a definite effect of this mutation on the CA125 level, prospective trials need to be conducted to define new cut-off levels of CA 125 in mutation carriers and optimize ovarian cancer screening. |
| first_indexed | 2024-03-13T01:54:48Z |
| format | Article |
| id | doaj.art-c71e31f709d24116840b3efd1810fae1 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-13T01:54:48Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-c71e31f709d24116840b3efd1810fae12023-07-02T11:18:26ZengBMCBMC Cancer1471-24072023-07-012311810.1186/s12885-023-11116-6CA125 Levels in BRCA mutation carriers – a retrospective single center cohort studyP Gebhart0CF Singer1D Gschwantler-Kaulich2Department of Obstetrics and Gynaecology, Comprehensive Cancer Center, Medical University of ViennaDepartment of Obstetrics and Gynaecology, Comprehensive Cancer Center, Medical University of ViennaDepartment of Obstetrics and Gynaecology, Comprehensive Cancer Center, Medical University of ViennaAbstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of carbohydrate antigen 125 (CA125) and transvaginal ultrasound (TVU), despite low sensitivity and specificity. We evaluated the association between CA125 levels, BRCA1/2 mutation status and menopausal status to provide more information on clinical conditions that may influence CA125 levels. Methods We retrospectively analyzed repeated measurements of CA125 levels and clinical data of 466 women at high risk for ovarian cancer. CA125 levels were compared between women with and without deleterious mutations in BRCA1/2. Pearson's correlation was used to determine the association between age and CA125 serum level. Differences in CA125 levels were assessed with the Mann–Whitney U test. The effect of BRCA1/2 mutation status and menopausal status on the change in CA125 levels was determined by Two-factor analysis of variance (ANOVA). Results The CA125 serum levels of premenopausal women (median, 13.8 kU/mL; range, 9.4 – 19.5 kU/mL) were significantly higher than in postmenopausal women (median, 10.4 kU/mL; range, 7.7 – 14.0 kU/mL; p < .001). There was no significant difference in the CA125 levels of BRCA mutation carriers and non-mutation carriers across all age groups (p = .612). When investigating the combined effect of BRCA1/2 mutation and menopausal status, variance analysis revealed a significant interaction between BRCA1/2 mutation status and menopausal status on CA125 levels (p < .001). There was a significant difference between the CA125 levels of premenopausal and postmenopausal women, with a large effect in BRCA mutation carriers (p < .001, d = 1.05), whereas in non-mutation carriers there was only a small effect (p < .001, d = 0.32). Conclusion Our findings suggest that hereditary mutations in BRCA1/2 affect the decline of CA125 levels with increasing age. To prove a definite effect of this mutation on the CA125 level, prospective trials need to be conducted to define new cut-off levels of CA 125 in mutation carriers and optimize ovarian cancer screening.https://doi.org/10.1186/s12885-023-11116-6CA-125 antigenGenes, BRCA1Genes, BRCA2Hereditary breast and ovarian cancer syndromeEarly detection of cancerOvarian neoplasms |
| spellingShingle | P Gebhart CF Singer D Gschwantler-Kaulich CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study BMC Cancer CA-125 antigen Genes, BRCA1 Genes, BRCA2 Hereditary breast and ovarian cancer syndrome Early detection of cancer Ovarian neoplasms |
| title | CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study |
| title_full | CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study |
| title_fullStr | CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study |
| title_full_unstemmed | CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study |
| title_short | CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study |
| title_sort | ca125 levels in brca mutation carriers a retrospective single center cohort study |
| topic | CA-125 antigen Genes, BRCA1 Genes, BRCA2 Hereditary breast and ovarian cancer syndrome Early detection of cancer Ovarian neoplasms |
| url | https://doi.org/10.1186/s12885-023-11116-6 |
| work_keys_str_mv | AT pgebhart ca125levelsinbrcamutationcarriersaretrospectivesinglecentercohortstudy AT cfsinger ca125levelsinbrcamutationcarriersaretrospectivesinglecentercohortstudy AT dgschwantlerkaulich ca125levelsinbrcamutationcarriersaretrospectivesinglecentercohortstudy |